Silexion Therapeutics Corp (SLXN)

$0.60 -0.03 (-4.79%)
Market Cap 2.11M
Revenue (ttm) 0.00
Net Income (ttm) -11.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.60
Volume 112,000
Avg Vol 69,430
Day's Range N/A - N/A
Shares Out 3.33M
Stochastic %K 26%
Beta -0.29
Analysts Strong Sell
Price Target $6.00

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 674 3430
Fax: 972 2 643 0982
Address:
The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 6:33 PM
$SLXN RSI: 18.30, MACD: -0.1870 Vol: 0.20, MA20: 0.88, MA50: 1.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
FU_Pay_Me_
FU_Pay_Me_ Apr. 30 at 12:29 PM
$SLXN Short interest is low, wonder what is driving the downturn. Citadel bought 12,000 shares recently, but it is not a short position.
1 · Reply
BullsGame
BullsGame Apr. 29 at 8:05 PM
$SLXN Does anybody know the result of the re-vote held on April 28, 2026?
1 · Reply
ZacksResearch
ZacksResearch Apr. 29 at 4:36 PM
$SLXN advances into Europe with key Phase 2/3 filing — here’s what investors should note The company submitted a CTA in Germany for its SIL204 candidate targeting KRAS-driven pancreatic cancer, supported by positive Scientific Advice and clean toxicology data, with trial initiation planned for the second quarter of 2026 across EU and Israeli sites. See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37943&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37943
0 · Reply
focafoca99
focafoca99 Apr. 28 at 6:40 PM
$SLXN submitted its SIL204 trial package to Germany's BfArM, marking a regulatory step forward for the program.
0 · Reply
WallStWireAds
WallStWireAds Apr. 28 at 12:47 PM
$SLXN https://caplynx.io/7CdUZly
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 28 at 8:37 AM
$SLXN
0 · Reply
FU_Pay_Me_
FU_Pay_Me_ Apr. 27 at 3:02 PM
$SLXN Taking a position here. Like to grab these that fall under a $1, because they always seem to magically pop one day for compliance.
0 · Reply
SavageJohnny
SavageJohnny Apr. 26 at 5:34 AM
$SLXN Upcoming Filings: The company plans to file for trial initiation in Germany by the end of Q2 2026, with broader EU filings targeted for early 2027.
0 · Reply
topstockalerts
topstockalerts Apr. 25 at 11:30 PM
After Hours Gainers $ADTX $DKI $NTLA $SLXN $WYHG
0 · Reply
Latest News on SLXN
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Apr 28, 2026, 8:45 AM EDT - 8 days ago

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Mar 24, 2026, 9:46 AM EDT - 6 weeks ago

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 17, 2026, 5:01 PM EDT - 7 weeks ago

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Dec 16, 2025, 8:40 AM EST - 5 months ago

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Nov 26, 2025, 7:30 AM EST - 5 months ago

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Nov 25, 2025, 9:15 AM EST - 5 months ago

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 9:00 AM EST - 6 months ago

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Sep 30, 2025, 8:40 AM EDT - 7 months ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Sep 25, 2025, 8:45 AM EDT - 7 months ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Sep 11, 2025, 1:26 PM EDT - 8 months ago

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Sep 11, 2025, 9:17 AM EDT - 8 months ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 11, 2025, 7:00 AM EDT - 8 months ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 4, 2025, 9:25 AM EDT - 8 months ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:45 AM EDT - 8 months ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 8:00 PM EDT - 9 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 31, 2025, 9:55 AM EDT - 9 months ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 16, 2025, 8:44 AM EDT - 10 months ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

Jul 9, 2025, 8:30 AM EDT - 10 months ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025, 3:46 PM EDT - 1 year ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 21, 2025, 8:45 AM EDT - 1 year ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:45 PM EDT - 1 year ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Apr 23, 2025, 9:20 AM EDT - 1 year ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 21, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 4:29 PM EDT - 1 year ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 17, 2025, 8:15 AM EDT - 1 year ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Mar 5, 2025, 12:05 PM EST - 1 year ago

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 5, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Mar 3, 2025, 8:30 AM EST - 1 year ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Feb 25, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 5:30 PM EST - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 29, 2025, 9:59 AM EST - 1 year ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 28, 2025, 8:29 AM EST - 1 year ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Jan 16, 2025, 12:08 PM EST - 1 year ago

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 11:04 AM EST - 1 year ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jan 16, 2025, 8:51 AM EST - 1 year ago

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LUV

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 8:00 PM EST - 1 year ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 15, 2025, 4:01 PM EST - 1 year ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 13, 2025, 7:50 AM EST - 1 year ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Dec 17, 2024, 9:36 AM EST - 1 year ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Oct 1, 2024, 6:45 AM EDT - 1 year ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Sep 24, 2024, 9:25 AM EDT - 1 year ago

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 9, 2024, 7:32 AM EDT - 1 year ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 6:33 PM
$SLXN RSI: 18.30, MACD: -0.1870 Vol: 0.20, MA20: 0.88, MA50: 1.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
FU_Pay_Me_
FU_Pay_Me_ Apr. 30 at 12:29 PM
$SLXN Short interest is low, wonder what is driving the downturn. Citadel bought 12,000 shares recently, but it is not a short position.
1 · Reply
BullsGame
BullsGame Apr. 29 at 8:05 PM
$SLXN Does anybody know the result of the re-vote held on April 28, 2026?
1 · Reply
ZacksResearch
ZacksResearch Apr. 29 at 4:36 PM
$SLXN advances into Europe with key Phase 2/3 filing — here’s what investors should note The company submitted a CTA in Germany for its SIL204 candidate targeting KRAS-driven pancreatic cancer, supported by positive Scientific Advice and clean toxicology data, with trial initiation planned for the second quarter of 2026 across EU and Israeli sites. See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37943&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37943
0 · Reply
focafoca99
focafoca99 Apr. 28 at 6:40 PM
$SLXN submitted its SIL204 trial package to Germany's BfArM, marking a regulatory step forward for the program.
0 · Reply
WallStWireAds
WallStWireAds Apr. 28 at 12:47 PM
$SLXN https://caplynx.io/7CdUZly
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 28 at 8:37 AM
$SLXN
0 · Reply
FU_Pay_Me_
FU_Pay_Me_ Apr. 27 at 3:02 PM
$SLXN Taking a position here. Like to grab these that fall under a $1, because they always seem to magically pop one day for compliance.
0 · Reply
SavageJohnny
SavageJohnny Apr. 26 at 5:34 AM
$SLXN Upcoming Filings: The company plans to file for trial initiation in Germany by the end of Q2 2026, with broader EU filings targeted for early 2027.
0 · Reply
topstockalerts
topstockalerts Apr. 25 at 11:30 PM
After Hours Gainers $ADTX $DKI $NTLA $SLXN $WYHG
0 · Reply
topstockalerts
topstockalerts Apr. 25 at 1:46 AM
After Hours Top Gainers $DKI $ADTX $WYHG $NTLA $SLXN
0 · Reply
Repo_Dennis
Repo_Dennis Apr. 17 at 3:50 PM
$SLXN not looking good unfortunately,
0 · Reply
captainblacktop
captainblacktop Apr. 14 at 3:25 PM
$SLXN this is getting painful...
1 · Reply
captainblacktop
captainblacktop Apr. 10 at 7:56 PM
$SLXN haha.. i own more than 1% of this company's stock.. 36K shares.. LET IT RIDE!!!
1 · Reply
SUGAO
SUGAO Apr. 10 at 2:23 AM
$SLXN I am a shareholder of SLXN, and I will be voting AGAINST all proposals
1 · Reply
Taajom
Taajom Apr. 9 at 7:24 PM
$SLXN https://truthsandnews.com/finance/why-is-slxn-stock-trending-today-april-2026-forecast-news-analysis
0 · Reply
captainblacktop
captainblacktop Apr. 9 at 2:33 PM
$SLXN dang 70,000 on the bid
0 · Reply
ZacksResearch
ZacksResearch Apr. 8 at 1:57 PM
$SLXN down 43% in 3 months — bargain buy or falling knife? ⚠️ Trading at a 12-month trailing P/B of 1.35 vs. industry average of 3.49 📉 while loss estimates for 2026 have narrowed over the past 30 days — early signs sentiment could be stabilizing. See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37688&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37688
0 · Reply
NarutoFox
NarutoFox Mar. 30 at 10:01 PM
$SLXN gaining momentum?
1 · Reply
2pumps1dump
2pumps1dump Mar. 25 at 10:31 PM
$SLXN bullish now that they can’t dilute the shit out of it. Need an exit asap. Increase equity incentive 😂
0 · Reply
WallStWireAds
WallStWireAds Mar. 25 at 1:50 PM
$SLXN Silexion Granted Approval to Launch Human Trials That Could Redefine the Future of Cancer Treatment https://www.benzinga.com/content/51430751/silexion-granted-approval-to-launch-human-trials-that-could-redefine-the-future-of-cancer-treatment
0 · Reply
captainblacktop
captainblacktop Mar. 24 at 4:07 PM
$SLXN Uno reverse it!
0 · Reply